skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Travoprost in the management of open-angle glaucoma and ocular hypertension

(3117) Views  (583) Full article downloads

Authors: Philippe Denis, David Covert, Anthony Realini

Published Date June 2007 Volume 2007:1(1) Pages 11 - 24
DOI: http://dx.doi.org/10.2147/OPTH.S

Philippe Denis1, David Covert2, Anthony Realini3

1Hôpital Edouard Herriot, Lyon, France; 2Alcon Research, Ltd., Fort Worth, TX, USA; 3West Virginia University Eye Institute, Morgantown, WV, USA

Abstract: Travoprost is a member of the prostaglandin analogue class of intraocular pressure (IOP)-lowering drugs used to treat ocular hypertension and glaucoma. Like other prostaglandin analogues, travoprost lowers IOP by enhancing the egress of aqueous humor through both the uveoscleral and trabecular outflow channels. This review summarizes the published data regarding the safety and efficacy of travoprost. Travoprost provides statistically significant and clinically relevant reductions in mean IOP, of the order of 6.5–9.0 mmHg in most studies. In addition, travoprost provides consistent diurnal IOP control, with statistically significant IOP reductions persisting up to 84 hours post-dose. Travoprost has a highly favorable safety profile; most adverse events are cosmetic in nature (such as iris hyperpigmentation and eyelash growth), although more serious adverse events (such as iritis and macular edema) have been associated with travoprost and the other prostaglandin drugs. In some markets, travoprost is available in a fixed combination with timolol; clinical studies have demonstrated that the fixed combination – dosed once daily – lowers IOP by 7–11.5 mmHg. In conclusion, travoprost provides safe and effective reduction of IOP, with convenient once-daily dosing, supporting its role as primary monotherapy.

Keywords: travoprost, prostaglandin analogue, glaucoma, ocular hypertension, treatment








Readers of this article also read:

Recognition of transorbital intracranial injury ||FREE PAPER||
Acquired color vision and visual field defects in patients with ocular hypertension and early glaucoma
Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis
Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives
Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine
Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from ß-blockers and prostaglandin analogs
Insight into 144 patients with ocular vascular events during VEGF antagonist injections
Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
Lamellar macular hole formation following vitrectomy for rhegmatogenous retinal detachment repair
Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy